These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 22527252)

  • 1. Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parameters.
    Aarntzen EH; de Vries IJ; Göertz JH; Beldhuis-Valkis M; Brouwers HM; van de Rakt MW; van der Molen RG; Punt CJ; Adema GJ; Tacken PJ; Joosten I; Jacobs JF
    Cancer Immunol Immunother; 2012 Nov; 61(11):2003-11. PubMed ID: 22527252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring of dynamic changes in Keyhole Limpet Hemocyanin (KLH)-specific B cells in KLH-vaccinated cancer patients.
    Wimmers F; de Haas N; Scholzen A; Schreibelt G; Simonetti E; Eleveld MJ; Brouwers HM; Beldhuis-Valkis M; Joosten I; de Jonge MI; Gerritsen WR; de Vries IJ; Diavatopoulos DA; Jacobs JF
    Sci Rep; 2017 Mar; 7():43486. PubMed ID: 28344338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21.
    Ragupathi G; Livingston PO; Hood C; Gathuru J; Krown SE; Chapman PB; Wolchok JD; Williams LJ; Oldfield RC; Hwu WJ
    Clin Cancer Res; 2003 Nov; 9(14):5214-20. PubMed ID: 14614001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer.
    Slovin SF; Ragupathi G; Musselli C; Fernandez C; Diani M; Verbel D; Danishefsky S; Livingston P; Scher HI
    Cancer Immunol Immunother; 2005 Jul; 54(7):694-702. PubMed ID: 15726361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor cell reactivity mediated by IgM antibodies in sera from melanoma patients vaccinated with GM2 ganglioside covalently linked to KLH is increased by IgG antibodies.
    Livingston P; Zhang S; Adluri S; Yao TJ; Graeber L; Ragupathi G; Helling F; Fleisher M
    Cancer Immunol Immunother; 1997 Jan; 43(6):324-30. PubMed ID: 9067403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine.
    MacLean GD; Reddish MA; Koganty RR; Longenecker BM
    J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):59-68. PubMed ID: 8859725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21.
    Ragupathi G; Meyers M; Adluri S; Howard L; Musselli C; Livingston PO
    Int J Cancer; 2000 Mar; 85(5):659-66. PubMed ID: 10699946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines.
    Livingston PO
    Immunol Rev; 1995 Jun; 145():147-66. PubMed ID: 7590824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study.
    Reichardt VL; Okada CY; Liso A; Benike CJ; Stockerl-Goldstein KE; Engleman EG; Blume KG; Levy R
    Blood; 1999 Apr; 93(7):2411-9. PubMed ID: 10090953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of keyhole limpet hemocyanin (KLH)-specific immune responses by intracellular cytokine assay in patients vaccinated with idiotype-KLH vaccine.
    Neelapu SS; Baskar S; Kwak LW
    J Cancer Res Clin Oncol; 2001 Oct; 127 Suppl 2():R14-9. PubMed ID: 11768619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunization with N-propionyl polysialic acid-KLH conjugate in patients with small cell lung cancer is safe and induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococci.
    Krug LM; Ragupathi G; Hood C; George C; Hong F; Shen R; Abrey L; Jennings HJ; Kris MG; Livingston PO
    Cancer Immunol Immunother; 2012 Jan; 61(1):9-18. PubMed ID: 21811785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mature dendritic cells induce T-helper type-1-dominant immune responses in patients with metastatic renal cell carcinoma.
    Rieser C; Ramoner R; Höltl L; Rogatsch H; Papesh C; Stenzl A; Bartsch G; Thurnher M
    Urol Int; 1999; 63(3):151-9. PubMed ID: 10738185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial.
    Santin AD; Bellone S; Palmieri M; Zanolini A; Ravaggi A; Siegel ER; Roman JJ; Pecorelli S; Cannon MJ
    J Virol; 2008 Feb; 82(4):1968-79. PubMed ID: 18057249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of canine T-cell dependent antibody response to the primary and secondary immunization with keyhole limpet hemocyanin.
    Kawai R; Aida T; Hattori H; Furukawa T; Mori K; Takasaki W; Takahashi N; Kawada T
    J Toxicol Sci; 2013; 38(4):571-9. PubMed ID: 23824013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel assay to measure B cell responses to keyhole limpet haemocyanin vaccination in healthy volunteers and subjects with systemic lupus erythematosus.
    Ferbas J; Belouski SS; Horner M; Kaliyaperumal A; Chen L; Boyce M; Colaço CB; McHugh N; Quick V; Nicholl RJ; Siu G; Chung J
    Br J Clin Pharmacol; 2013 Aug; 76(2):188-202. PubMed ID: 23731388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies.
    Yao TJ; Meyers M; Livingston PO; Houghton AN; Chapman PB
    Clin Cancer Res; 1999 Jan; 5(1):77-81. PubMed ID: 9918205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine.
    Timmerman JM; Levy R
    J Immunol; 2000 May; 164(9):4797-803. PubMed ID: 10779787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-lasting humoral immune response induced in HIV-1-infected patients by a synthetic peptide (AT20) derived from the HIV-1 matrix protein p17 functional epitope.
    Focà E; Iaria ML; Caccuri F; Fiorentini S; Motta D; Giagulli C; Castelli F; Caruso A
    HIV Clin Trials; 2015 Aug; 16(4):157-62. PubMed ID: 26057863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial.
    Oshita C; Takikawa M; Kume A; Miyata H; Ashizawa T; Iizuka A; Kiyohara Y; Yoshikawa S; Tanosaki R; Yamazaki N; Yamamoto A; Takesako K; Yamaguchi K; Akiyama Y
    Oncol Rep; 2012 Oct; 28(4):1131-8. PubMed ID: 22895835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune response induced in vitro by CD16- and CD16+ monocyte-derived dendritic cells in patients with metastatic renal cell carcinoma treated with dendritic cell vaccines.
    Arroyo JC; Gabilondo F; Llorente L; Meraz-Ríos MA; Sánchez-Torres C
    J Clin Immunol; 2004 Jan; 24(1):86-96. PubMed ID: 14997038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.